Novartis AG PE Ratio 2006-2018 | NVS

Current and historical p/e ratio for Novartis AG (NVS) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Novartis AG PE ratio as of January 22, 2019 is 17.62.
Novartis AG PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-01-22 88.32 15.49
2018-09-30 86.16 $5.70 15.12
2018-06-30 75.54 $5.89 12.83
2018-03-31 80.85 $3.41 23.71
2017-12-31 81.04 $3.25 24.94
2017-09-30 82.87 $2.81 29.49
2017-06-30 80.57 $2.74 29.40
2017-03-31 71.69 $2.66 26.95
2016-12-31 67.87 $2.80 24.24
2016-09-30 73.57 $2.84 25.91
2016-06-30 76.88 $2.80 27.46
2016-03-31 67.50 $2.80 24.11
2015-12-31 77.20 $7.28 10.60
2015-09-30 82.47 $7.45 11.07
2015-06-30 88.23 $7.99 11.04
2015-03-31 88.48 $8.27 10.70
2014-12-31 80.86 $4.14 19.53
2014-09-30 82.14 $4.35 18.88
2014-06-30 79.00 $3.94 20.05
2014-03-31 74.19 $3.94 18.83
2013-12-31 67.88 $3.72 18.25
2013-09-30 64.78 $3.73 17.37
2013-06-30 59.71 $3.84 15.55
2013-03-31 60.16 $3.92 15.35
2012-12-31 51.50 $3.90 13.21
2012-09-30 49.84 $3.55 14.04
2012-06-30 45.48 $3.55 12.81
2012-03-31 45.08 $3.55 12.70
2011-12-31 44.52 $3.80 11.72
2011-09-30 43.43 $4.26 10.20
2011-06-30 47.59 $4.24 11.22
2011-03-31 42.33 $4.19 10.10
2010-12-31 44.02 $4.28 10.29
2010-09-30 43.07 $4.35 9.90
2010-06-30 36.08 $4.28 8.43
2010-03-31 40.40 $4.11 9.83
2009-12-31 39.21 $3.69 10.63
2009-09-30 36.29 $3.34 10.87
2009-06-30 29.38 $3.34 8.80
2009-03-31 27.25 $3.44 7.92
2008-12-31 34.33 $3.59 9.56
2008-09-30 36.45 $3.34 10.91
2008-06-30 37.97 $5.39 7.04
2008-03-31 35.34 $5.26 6.72
2007-12-31 36.40 $5.16 7.05
2007-09-30 36.83 $5.45 6.76
2007-06-30 37.58 $3.28 11.46
2007-03-31 36.61 $3.15 11.62
2006-12-31 37.78 $3.06 12.35
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $205.567B $49.109B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $350.628B 16.44
Pfizer (PFE) United States $253.175B 14.27
Merck (MRK) United States $204.560B 17.73
AbbVie (ABBV) United States $134.627B 11.95
Eli Lilly (LLY) United States $123.506B 21.71
Novo Nordisk (NVO) Denmark $117.412B 19.07
Sanofi (SNY) France $104.035B 12.88
GlaxoSmithKline (GSK) United Kingdom $96.892B 13.02
AstraZeneca (AZN) United Kingdom $92.577B 11.49
Bristol-Myers Squibb (BMY) United States $81.806B 13.47